NASDAQ:SGMO

Sangamo Therapeutics Competitors

$11.48
-0.29 (-2.46 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$11.33
Now: $11.48
$11.85
50-Day Range
$10.88
MA: $11.80
$13.59
52-Week Range
$7.03
Now: $11.48
$19.43
Volume857,125 shs
Average Volume1.51 million shs
Market Capitalization$1.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97

Competitors

Sangamo Therapeutics (NASDAQ:SGMO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying SGMO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Sangamo Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Amgen and Sangamo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.30$7.84 billion$14.8217.25
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51

Amgen has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Sangamo Therapeutics-51.51%-16.32%-9.85%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amgen and Sangamo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen091402.61
Sangamo Therapeutics02402.67

Amgen presently has a consensus price target of $261.0476, indicating a potential upside of 1.67%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Amgen.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Amgen beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Gilead Sciences and Sangamo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51

Gilead Sciences has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Sangamo Therapeutics-51.51%-16.32%-9.85%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gilead Sciences and Sangamo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
Sangamo Therapeutics02402.67

Gilead Sciences presently has a consensus price target of $97.92, indicating a potential upside of 46.43%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Gilead Sciences.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Gilead Sciences beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vertex Pharmaceuticals and Sangamo Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Sangamo Therapeutics02402.67

Vertex Pharmaceuticals presently has a consensus price target of $293.1250, indicating a potential upside of 32.98%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Vertex Pharmaceuticals.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Sangamo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51

Vertex Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Sangamo Therapeutics-51.51%-16.32%-9.85%

Summary

Vertex Pharmaceuticals beats Sangamo Therapeutics on 11 of the 15 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Regeneron Pharmaceuticals051412.80

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Regeneron Pharmaceuticals has a consensus price target of $646.2609, indicating a potential upside of 28.58%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Regeneron Pharmaceuticals.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41

Regeneron Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Summary

Regeneron Pharmaceuticals beats Sangamo Therapeutics on 12 of the 15 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Biogen5141202.23

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Biogen has a consensus price target of $303.5862, indicating a potential upside of 12.12%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Biogen.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51
Biogen$14.38 billion2.86$5.89 billion$33.578.05

Biogen has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
Biogen35.63%51.00%23.54%

Summary

Biogen beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Alexion Pharmaceuticals017512.30

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 6.00%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Alexion Pharmaceuticals.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80

Alexion Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Alexion Pharmaceuticals beats Sangamo Therapeutics on 11 of the 15 factors compared between the two stocks.


Sangamo Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.71-0.2%$147.24 billion$23.36 billion20.62Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87-1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39-0.8%$56.78 billion$4.16 billion27.70
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60-1.6%$53.84 billion$7.86 billion18.37Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.31-0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68-3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50-2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04-0.4%$21.99 billion$876.29 million-58.84
Incyte logo
INCY
Incyte
1.7$82.68-0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35-11.1%$16.79 billion$18.66 million-43.55
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.29-0.5%$16.31 billion$219.75 million-17.66
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.92-0.2%$14.32 billion$1.70 billion18.06
Repligen logo
RGEN
Repligen
1.5$212.68-0.4%$11.70 billion$270.24 million259.37
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.85-1.1%$8.98 billion$1.45 billion19.29Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.22-0.0%$6.62 billion$195.99 million288.88Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31-5.3%$2.05 billion$638.60 million-10.50
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Codexis logo
CDXS
Codexis
1.3$23.60-4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02
Innoviva logo
INVA
Innoviva
1.4$11.64-2.1%$1.21 billion$261.02 million5.94
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.23-1.7%$1.07 billion$63.04 million-20.14Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.55-0.0%$932.93 million$3.57 million-10.56Analyst Upgrade
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.96-5.0%$752.08 million$322.07 million-4.72Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$461.78 million$17.46 million-1.90
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$37.06-2.1%$426.12 million$18.37 million-33.39Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.14-7.2%$421.39 million$36.63 million-4.87Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.